Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Asian Markets Slip as AI Spending Fears Shake Tech, Wall Street Futures Rebound 
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
KT Corp. has collaborated with US-based NeuroSigma Inc. to build a business model and technology for electronic medicine to treat neurological disorders, such as attention deficit hyperactivity disorder (ADHD), depression, and epilepsy.
Under the partnership, KTS will support the development of the next version of NeuroSigma's external trigeminal nerve stimulation (eTNS®) system while producing and commercializing the device in South Korea.
NeuoSigma is credited for developing the first device cleared by the US Food and Drug Administration to treat pediatric ADHD--the Monarch external Trigeminal Nerve Stimulation system,
The telecom operator said NeuoSigma's pediatric ADHD electronic treatment has fewer side effects than other existing medication and is set to receive further clearance from the FDA on depression and epilepsy treatment using the technology.
